187 related articles for article (PubMed ID: 15728441)
1. Sudden death in a patient with Tourette syndrome during a clinical trial of ziprasidone.
Scahill L; Blair J; Leckman JF; Martin A
J Psychopharmacol; 2005 Mar; 19(2):205-6. PubMed ID: 15728441
[No Abstract] [Full Text] [Related]
2. Tourette syndrome: efficient treatment with ziprasidone and normalization of body weight in a patient with excessive weight gain under tiapride.
Meisel A; Winter C; Zschenderlein R; Arnold G
Mov Disord; 2004 Aug; 19(8):991-2. PubMed ID: 15300676
[No Abstract] [Full Text] [Related]
3. Parenteral ziprasidone: a new atypical neuroleptic for emergency treatment of psychosis in Parkinson's disease?
Oechsner M; Korchounov A
Hum Psychopharmacol; 2005 Apr; 20(3):203-5. PubMed ID: 15799011
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
Ratner Y; Gibel A; Yorkov V; Ritsner MS
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1401-9. PubMed ID: 17669574
[TBL] [Abstract][Full Text] [Related]
5. Parkinsonism with intramuscular ziprasidone.
Bilal L; Tsai C; Gasper JJ; Ndlela JC
Am J Psychiatry; 2005 Dec; 162(12):2392-3. PubMed ID: 16330610
[No Abstract] [Full Text] [Related]
6. Switching among antipsychotics in everyday clinical practice: focus on ziprasidone.
Rossi A; Cañas F; Fagiolini A; Larmo I; Levy P; Montes JM; Papageorgiou G; Sturlason R; Zink M; Correll CU
Postgrad Med; 2011 Jan; 123(1):135-59. PubMed ID: 21293094
[TBL] [Abstract][Full Text] [Related]
7. Strategies for successful clinical management of schizophrenia with ziprasidone.
Fagiolini A; Cañas F; Gallhofer B; Larmo I; Levy P; Montes JM; Papageorgiou G; Zink M; Rossi A
Expert Opin Pharmacother; 2010 Sep; 11(13):2199-220. PubMed ID: 20658947
[TBL] [Abstract][Full Text] [Related]
8. Activation induced by high-dose ziprasidone: a case report.
Kaushik S; Maccabee N; Kaushik S; Lindenmayer JP
J Clin Psychiatry; 2009 Sep; 70(9):1326-7. PubMed ID: 19818257
[No Abstract] [Full Text] [Related]
9. Electrocardiographic changes with ziprasidone.
Loebel A; Miceli J; Chappell P; Siu C
J Am Acad Child Adolesc Psychiatry; 2006 Jun; 45(6):636-637. PubMed ID: 16721311
[No Abstract] [Full Text] [Related]
10. A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia.
Arango C; Gómez-Beneyto M; Brenlla J; Gastó C; Sarramea-Crespo F; Chamorro L; Masramon X; Díez T;
Eur Neuropsychopharmacol; 2007; 17(6-7):456-63. PubMed ID: 17234389
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial.
Zink M; Kuwilsky A; Krumm B; Dressing H
J Psychopharmacol; 2009 May; 23(3):305-14. PubMed ID: 18562423
[TBL] [Abstract][Full Text] [Related]
12. A case report with ziprasidone-induced catatonic symptoms.
Markham-Abedi C; McNeely C; de Leon J
J Neuropsychiatry Clin Neurosci; 2007; 19(4):476-7. PubMed ID: 18070860
[No Abstract] [Full Text] [Related]
13. Naturalistic study of intramuscular ziprasidone versus conventional agents in agitated elderly patients: retrospective findings from a psychiatric emergency service.
Kohen I; Preval H; Southard R; Francis A
Am J Geriatr Pharmacother; 2005 Dec; 3(4):240-5. PubMed ID: 16503319
[TBL] [Abstract][Full Text] [Related]
14. Ziprasidone hydrochloride.
Am J Health Syst Pharm; 2002 Jan; 59(1):28-9. PubMed ID: 11813463
[No Abstract] [Full Text] [Related]
15. Pharmacodynamics of ziprasidone in children and adolescents: impact on dopamine transmission.
Sallee FR; Gilbert DL; Vinks AA; Miceli JJ; Robarge L; Wilner K
J Am Acad Child Adolesc Psychiatry; 2003 Aug; 42(8):902-7. PubMed ID: 12874491
[TBL] [Abstract][Full Text] [Related]
16. Ziprasidone in adolescents with autism: an open-label pilot study.
Malone RP; Delaney MA; Hyman SB; Cater JR
J Child Adolesc Psychopharmacol; 2007 Dec; 17(6):779-90. PubMed ID: 18315450
[TBL] [Abstract][Full Text] [Related]
17. Possible serotonin syndrome with citalopram following cross-titration of clozapine to ziprasidone.
Kinzie E; Meltzer-Brody S
Gen Hosp Psychiatry; 2005; 27(3):223-4. PubMed ID: 15882772
[No Abstract] [Full Text] [Related]
18. Ziprasidone-related neuroleptic malignant syndrome in a patient with Parkinson's disease: a diagnostic challenge.
Gray NS
Hum Psychopharmacol; 2004 Apr; 19(3):205-7. PubMed ID: 15079855
[TBL] [Abstract][Full Text] [Related]
19. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
Cutler AJ; Kalali AH; Weiden PJ; Hamilton J; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S20-8. PubMed ID: 18334909
[TBL] [Abstract][Full Text] [Related]
20. A case of catatonia successfully treated with ziprasidone, in a patient with DSM-IV delusional disorder.
Angelopoulos EK; Corcondilas M; Kollias CT; Kioulos KT; Bergiannaki JD; Papadimitriou GN
J Clin Psychopharmacol; 2010 Dec; 30(6):745-6. PubMed ID: 21057243
[No Abstract] [Full Text] [Related]
[Next] [New Search]
